Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 10, 2026, 11:54 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 3,626 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Gastrointestinal Disease Symptoms Clear all
Completed Phase 3 Interventional Results available

Clinical Trial Testing TH-302 in Combination With Gemcitabine in Previously Untreated Subjects With Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma

NCT01746979
View directory record Official record
Conditions
Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma
Interventions
TH-302, Gemcitabine, Placebo (5 percent dextrose - D5W)
Drug
Lead sponsor
ImmunoGenesis
Industry
Eligibility
18 Years and older
Enrollment
693 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Rockland, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 11, 2025 · Synced Oct 10, 2026, 11:54 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Hyperpolarized Noble Gas MR Imaging for Pulmonary Disorders

NCT00846573
View directory record Official record
Conditions
COPD, Cystic Fibrosis, Asthma, Healthy
Interventions
Hyperpolarized Helium-3
Drug
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
5 Years and older
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 15, 2012 · Synced Oct 10, 2026, 11:54 PM EDT
Terminated Phase 3 Interventional Results available

The Safety and Tolerability of Budesonide Foam in Participants With Active Ulcerative Proctitis or Proctosigmoiditis

NCT01349673
View directory record Official record
Conditions
Proctitis, Proctosigmoiditis
Interventions
Budesonide Foam
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 14, 2019 · Synced Oct 10, 2026, 11:54 PM EDT
Active, not recruiting Phase 1 Interventional

Study of TPX-0022 in Patients With Advanced NSCLC, Gastric Cancer or Solid Tumors Harboring Genetic Alterations in MET

NCT03993873
View directory record Official record
Conditions
Advanced Solid Tumor, Metastatic Solid Tumors, MET Gene Alterations
Interventions
elzovantinib (TPX-0022)
Drug
Lead sponsor
Turning Point Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
12
States / cities
La Jolla, California • Orange, California • Denver, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2025 · Synced Oct 10, 2026, 11:54 PM EDT
Completed Phase 4 Interventional Results available

A Study on the Correlation Between Interleukin 28B Genotypes With Clinical and Demographic Characteristics in Treatment-Naïve and Treatment-Experienced Patients With Chronic Hepatitis C

NCT01675427
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
Interleukin 28B testing
Other
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
4,766 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Alexandria, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 26, 2015 · Synced Oct 10, 2026, 11:54 PM EDT
Terminated Not applicable Interventional

SCP vs HUSLS for Pelvic Organ Prolapse Repair

NCT02800512
View directory record Official record
Conditions
Pelvic Organ Prolapse, Cystocele, Rectocele, Enterocele
Interventions
Robotic sacrocolpopexy, high uterosacral ligament suspension
Procedure
Lead sponsor
Loma Linda University
Other
Eligibility
18 Years to 100 Years · Female only
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Oct 10, 2026, 11:54 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Study of Erythromycin in GER-Associated Apnea of the Newborn

NCT01825473
View directory record Official record
Conditions
Gastroesophageal Reflux, Apnea, Bradycardia
Interventions
Erythromycin, Multi-channel intra-luminal impedance (MII) pH monitoring, Placebo (D5W)
Drug · Device
Lead sponsor
University of Virginia
Other
Eligibility
14 Days and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 5, 2013 · Synced Oct 10, 2026, 11:54 PM EDT
Completed Phase 2 Interventional

A Study to Evaluate the Safety, Tolerability and Pharmacodynamics of Pumosetrag in Patients With Gastroesophageal Reflux Disease (GERD)

NCT01161602
View directory record Official record
Conditions
Gastroesophageal Reflux Disease
Interventions
Pumosetrag, Placebo
Drug · Other
Lead sponsor
Edusa Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2011
U.S. locations
5
States / cities
Scottsdale, Arizona • Anaheim, California • Jacksonville, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2011 · Synced Oct 10, 2026, 11:54 PM EDT
Completed Phase 3 Interventional

Evaluate Efficacy, Safety and PK of Adefovir Dipivoxil Liquid Suspension in Patients With Chronic Hepatitis B

NCT00071201
View directory record Official record
Conditions
Chronic Hepatitis B
Interventions
Adefovir Dipivoxil for oral suspension, 2 mg/mL
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Foster City, California
Source: ClinicalTrials.gov public record
Updated Oct 16, 2013 · Synced Oct 10, 2026, 11:54 PM EDT
Terminated Not applicable Interventional

Study to Intervene With Nutrition for Gastroparesis

NCT03987672
View directory record Official record
Conditions
Gastroparesis
Interventions
Assess the nutritional effects of the Kate Farm Peptide 1.5 nutritional Formula
Dietary Supplement
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 65 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Redwood City, California
Source: ClinicalTrials.gov public record
Updated Aug 22, 2022 · Synced Oct 10, 2026, 11:54 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Safety and Efficacy of Cotadutide Given by Subcutaneous Injection in Adult Participants With Non-cirrhotic Non-alcoholic Steatohepatitis With Fibrosis

NCT05364931
View directory record Official record
Conditions
Non-cirrhotic Non-alcoholic Steatohepatitis With Fibrosis
Interventions
Cotadutide, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
29
States / cities
Tucson, Arizona • Canoga Park, California • Gilroy, California + 23 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2025 · Synced Oct 10, 2026, 11:54 PM EDT
Completed Phase 2 Interventional Results available

Safety, Tolerability and Antiviral Activity of Selgantolimod in Virally-Suppressed Participants With Chronic Hepatitis B

NCT03491553
View directory record Official record
Conditions
Chronic Hepatitis B
Interventions
Selgantolimod, Placebo, Hepatitis B virus (HBV) OAV Therapy
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 19, 2021 · Synced Oct 10, 2026, 11:54 PM EDT
Terminated Phase 2 Interventional Results available

Futibatinib in Patients With Specific FGFR Aberrations

NCT04189445
View directory record Official record
Conditions
Advanced or Metastatic Solid Tumor, Advanced or Metastatic Gastric or Gastroesophageal Cancer, Myeloid or Lymphoid Neoplasms (MLN)
Interventions
Futibatinib
Drug
Lead sponsor
Taiho Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
11
States / cities
Gilbert, Arizona • Los Angeles, California • Washington D.C., District of Columbia + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2025 · Synced Oct 10, 2026, 11:54 PM EDT
Completed Phase 3 Interventional Results available

Entecavir Plus Tenofovir Combination Therapy Versus Entecavir Monotherapy in Naive Subjects With Chronic Hepatitis B

NCT00410072
View directory record Official record
Conditions
Hepatitis B, Chronic
Interventions
Entecavir, Entecavir + Tenofovir
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
16 Years and older
Enrollment
669 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
16
States / cities
Los Angeles, California • San Diego, California • San Jose, California + 10 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2013 · Synced Oct 10, 2026, 11:54 PM EDT
Completed No phase listed Observational Results available

Gastrointestinal Symptoms in Postural Orthostatic Tachycardia Syndrome

NCT03263819
View directory record Official record
Conditions
Postural Tachycardia Syndrome
Interventions
Oral glucose tolerance test
Diagnostic Test
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 60 Years · Female only
Enrollment
26 participants
Timeline
2017 – 2020
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 8, 2024 · Synced Oct 10, 2026, 11:54 PM EDT
Terminated Phase 1 Interventional

An Open-Label Study of a Novel JAK-inhibitor, INCB047986, Given in Patients With Advanced Malignancies

NCT01929941
View directory record Official record
Conditions
Solid Tumor, Hodgkin's Lymphoma, NHL (Non-Hodgkin Lymphoma), Pancreatic Cancer, Breast Cancer, UC (Ureter and Urethera), Advanced Cancer, Metastatic Cancer
Interventions
INCB047986, Gemcitabine, nab-paclitaxel
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
3
States / cities
Atlanta, Georgia • Nashville, Tennessee • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 17, 2018 · Synced Oct 10, 2026, 11:54 PM EDT
Terminated Phase 2 Interventional Results available

Safety and Efficacy of Simtuzumab (SIM, GS-6624) in Adults With Advanced Liver Fibrosis But Not Cirrhosis Secondary to Non-Alcoholic Steatohepatitis (NASH)

NCT01672866
View directory record Official record
Conditions
Liver Fibrosis Due to NASH
Interventions
Placebo, SIM
Biological
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
41
States / cities
Phoenix, Arizona • Coronado, California • San Diego, California + 34 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2019 · Synced Oct 10, 2026, 11:54 PM EDT
Not listed Phase 2 Interventional

Emricasan, a Caspase Inhibitor, for Treatment of Subjects With Decompensated NASH Cirrhosis

NCT03205345
View directory record Official record
Conditions
Decompensated Cirrhosis
Interventions
Emricasan (25 mg), Emricasan (5 mg), Placebo
Drug
Lead sponsor
Conatus Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
76
States / cities
Chandler, Arizona • Phoenix, Arizona • Tucson, Arizona + 59 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2019 · Synced Oct 10, 2026, 11:54 PM EDT
Completed No phase listed Observational

Prevalence of Liver Disease in Patients Dependent on Parenteral Nutrition

NCT05011370
View directory record Official record
Conditions
Intestinal Failure-associated Liver Disease
Interventions
Not listed
Lead sponsor
Protara Therapeutics
Industry
Eligibility
12 Years to 80 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
10
States / cities
Los Angeles, California • Kissimmee, Florida • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 3, 2023 · Synced Oct 10, 2026, 11:54 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Panitumumab and Bortezomib for Patients With Advanced Colorectal Cancer

NCT01504477
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Panitumumab and bortezomib
Drug
Lead sponsor
Georgetown University
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Mar 16, 2020 · Synced Oct 10, 2026, 11:54 PM EDT
Completed No phase listed Observational

Efficacy of Psychological Therapies in Patients With Functional Bowel Disorders

NCT04060121
View directory record Official record
Conditions
IBS - Irritable Bowel Syndrome, Constipation
Interventions
Not listed
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Apr 29, 2024 · Synced Oct 10, 2026, 11:54 PM EDT
Terminated Phase 1 Interventional

A Study of 1018 Immunostimulatory Sequence (ISS) Administered With Irinotecan and Cetuximab to Treat Patients With Previously Treated Metastatic Colorectal Cancer

NCT00403052
View directory record Official record
Conditions
Colorectal Neoplasms
Interventions
1018 ISS immunostimulatory oligonucleotide
Drug
Lead sponsor
Dynavax Technologies Corporation
Industry
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
3
States / cities
Santa Monica, California • Washington D.C., District of Columbia • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 16, 2019 · Synced Oct 10, 2026, 11:54 PM EDT
Withdrawn No phase listed Observational

A Real-World Data Study to Evaluate the Effectiveness of OCA on Hepatic Outcomes in PBC Patients

NCT05293938
View directory record Official record
Conditions
Primary Biliary Cholangitis
Interventions
Obeticholic Acid 5 MG, Obeticholic Acid 10 MG, Standard of Care: UDCA
Drug
Lead sponsor
Intercept Pharmaceuticals
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Oct 10, 2023 · Synced Oct 10, 2026, 11:54 PM EDT
Completed Phase 2 Interventional Results available

A Phase IIb Study to Evaluate the Safety of Zibotentan/Dapagliflozin in Participants With Cirrhosis-ZEAL-UNLOCK

NCT06269484
View directory record Official record
Conditions
Liver Cirrhosis
Interventions
Placebo (placebo matching zibotentan capsule and placebo matching dapagliflozin tablet), Zibotentan + placebo (placebo matching dapagliflozin tablet), Zibotentan + dapagliflozin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 80 Years
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
3
States / cities
Englewood, Colorado • Charleston, South Carolina • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 20, 2026 · Synced Oct 10, 2026, 11:54 PM EDT